ATE296286T1 - Morpholino-n-ethyl ester prodrogen von indol spla 2 hemmer - Google Patents

Morpholino-n-ethyl ester prodrogen von indol spla 2 hemmer

Info

Publication number
ATE296286T1
ATE296286T1 AT98955125T AT98955125T ATE296286T1 AT E296286 T1 ATE296286 T1 AT E296286T1 AT 98955125 T AT98955125 T AT 98955125T AT 98955125 T AT98955125 T AT 98955125T AT E296286 T1 ATE296286 T1 AT E296286T1
Authority
AT
Austria
Prior art keywords
indol
ethyl ester
morpholino
prodrogen
spla
Prior art date
Application number
AT98955125T
Other languages
German (de)
English (en)
Inventor
Michael Lyle Denney
John Michael Morin Jr
Daniel Jon Sall
Jason Scott Sawyer
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE296286T1 publication Critical patent/ATE296286T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
AT98955125T 1997-10-27 1998-10-26 Morpholino-n-ethyl ester prodrogen von indol spla 2 hemmer ATE296286T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6364697P 1997-10-27 1997-10-27
PCT/US1998/022679 WO1999021559A1 (en) 1997-10-27 1998-10-26 MORPHOLINO-N-ETHYL ESTER PRODRUGS OF INDOLE sPLA2 INHIBITORS

Publications (1)

Publication Number Publication Date
ATE296286T1 true ATE296286T1 (de) 2005-06-15

Family

ID=22050578

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98955125T ATE296286T1 (de) 1997-10-27 1998-10-26 Morpholino-n-ethyl ester prodrogen von indol spla 2 hemmer

Country Status (9)

Country Link
US (1) US6177426B1 (enExample)
EP (1) EP1039911B1 (enExample)
JP (1) JP2001520998A (enExample)
AT (1) ATE296286T1 (enExample)
AU (1) AU1200899A (enExample)
CA (1) CA2308443A1 (enExample)
DE (1) DE69830335T2 (enExample)
ES (1) ES2241178T3 (enExample)
WO (1) WO1999021559A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1200899A (en) 1997-10-27 1999-05-17 Eli Lilly And Company Morpholino-n-ethyl ester prodrugs of indole spla2 inhibitors
US6274578B1 (en) 1999-04-20 2001-08-14 Eli Lilly And Company sPLA2 inhibitor ester
US6140327A (en) * 1999-05-12 2000-10-31 Eli Lilly And Company Morpholino-n-ethyl ester derivative of an indole sPLA2 inhibitor
DE60032774D1 (de) * 1999-07-19 2007-02-15 Lilly Co Eli Spla2 inhibitoren
US6706752B1 (en) 1999-07-19 2004-03-16 Eli Lilly And Company sPLA2 inhibitors
US6831095B1 (en) 1999-09-20 2004-12-14 Eli Lilly And Company Hydroxyfunctional amide 1h-indole derivatives active as sPLA2 inhibitors
DE60032254D1 (de) * 1999-09-20 2007-01-18 Lilly Co Eli Hydroxyfunktionelle amid-1h-indolderivate aktiv als spla2 inhibitoren
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
EP1303262A2 (en) * 2000-07-14 2003-04-23 Eli Lilly And Company Use of a spla2 inhibitor for the treatment of sepsis
US20030124174A1 (en) * 2001-10-25 2003-07-03 Endo Pharmaceuticals, Inc Method for treating non-neuropathic pain
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
EP4008327A1 (en) 2009-04-29 2022-06-08 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
EP2887934A1 (en) * 2012-08-22 2015-07-01 XenoPort, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
US20140348915A9 (en) 2012-08-22 2014-11-27 Xenoport, Inc. Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
US9416096B2 (en) 2013-09-06 2016-08-16 Xenoport, Inc. Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) * 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CA3013407A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EA201992782A1 (ru) 2017-05-22 2020-03-24 Янссен Фармасьютикалз, Инк. Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
EA039702B1 (ru) 2017-05-22 2022-03-01 Янссен Фармасьютикалз, Инк. Замещенные производные индолина в качестве ингибиторов репликации вирусов денге

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE220394T1 (de) 1994-04-01 2002-07-15 Lilly Co Eli 1h-indol-3-glyoxylamid spla2 inhibitoren
US5972988A (en) 1997-03-26 1999-10-26 Eli Lilly And Company Method for treatment of chronic bronchitis using indole compounds
AU1200899A (en) 1997-10-27 1999-05-17 Eli Lilly And Company Morpholino-n-ethyl ester prodrugs of indole spla2 inhibitors
AU1200799A (en) * 1997-10-27 1999-05-17 Eli Lilly And Company Isopropyl ester prodrugs of indole spla2 inhibitors
CA2310249A1 (en) 1997-11-14 1999-05-27 August Masaru Watanabe Treatment for alzheimer's disease

Also Published As

Publication number Publication date
US6177426B1 (en) 2001-01-23
CA2308443A1 (en) 1999-05-06
WO1999021559A1 (en) 1999-05-06
EP1039911B1 (en) 2005-05-25
JP2001520998A (ja) 2001-11-06
AU1200899A (en) 1999-05-17
EP1039911A1 (en) 2000-10-04
DE69830335T2 (de) 2006-02-02
EP1039911A4 (en) 2002-07-17
ES2241178T3 (es) 2005-10-16
DE69830335D1 (de) 2005-06-30

Similar Documents

Publication Publication Date Title
ATE296286T1 (de) Morpholino-n-ethyl ester prodrogen von indol spla 2 hemmer
ATE540923T1 (de) Ää3-(2-amino-1,2-dioxoethyl)-2-ethyl-1- (phenylmethyl)-11h-indol-4-ylüoxyüessigsäure methyl ester als spla2 inhibitor
RU94012931A (ru) Гидразиды 1н-индол-3-уксусной кислоты как ингибиторы spla2
DE69724009D1 (de) PYRROLE ALS sPLA2 INHIBITOREN
FI941767A0 (fi) 1H-indoli-3-asetamidi sPLA2 inhibiittoreita
ATE203744T1 (de) Naphthyl-acetamide als spla2-inhibitoren
EP1100492A4 (en) SPLA 2 INHIBITORS? INDOLE TYPE
ATE234850T1 (de) Phenylglyoxamide als spla2-inhibitoren
ATE280155T1 (de) Inhibitorische ester für spla 2
DE60032774D1 (de) Spla2 inhibitoren
BR0010448A (pt) éster de morfolino-n-etila derivado de um inibidor de spla2 de indol
WO2000037472A3 (en) Substituted pirroloindoles
ATE353876T1 (de) Substituierte carbazole als inhibitoren von spla2
AU7053700A (en) Novel spla2 inhibitors
WO2002050028A8 (en) Substituted benzoindoles as spla2 inhibitors
WO2001049662A3 (en) Carbazole derivatives as inhibitors of spla2
DE60126831D1 (de) Benz(g)indole und deren verwendung als spla2 inhibitoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties